Anzeige
Erschienen in:
01.11.2009 | Original Paper
Adenosine-induced maximal coronary hyperemia for myocardial fractional flow reserve measurements: comparison of administration by femoral venous versus antecubital venous access
Erschienen in: Clinical Research in Cardiology | Ausgabe 11/2009
Einloggen, um Zugang zu erhaltenAbstract
Background
Maximal hyperemia is a critical prerequisite for correct fractional flow reserve (FFR) measurements. Continuous administration of adenosine by femoral venous access is considered the gold-standard. However, antecubital venous access is used as an alternative route of administration due to the increasing popularity of radial versus femoral access for coronary catheterization. Because of a potentially larger cross sectional venous area in the arm—theoretically associated with slower flow velocities—and the extremely short half-life of adenosine, there are concerns whether this route of administration is truly equivalent to the femoral route.
Methods
Fifty randomly selected patients with coronary artery disease were included. FFR was measured with a pressure monitoring wire and the recording was digitally stored. Hyperemia was successively induced by adenosine via the antecubital vein at a dose of 140 μg kg−1 min−1 (A140), via the antecubital vein at a dose of 170 μg kg−1 min−1 (A170), and via the femoral vein at a dose of 140 μg kg−1 min−1 (F140).
Results
Induction of hyperemia by A140 yielded significantly lower hyperemic responses than compared with A170 (P = 0.038) and F140 (P = 0.005). No significant difference was seen between adenosine administration by A170 versus F140. Hyperemic stimulation by A140 underestimated lesion severity near the ischemic threshold of FFR more frequently than the other modalities. There were no differences in side-effects between any of the dosages and routes of administration.
Conclusions
The intravenous application of adenosine via antecubital venous access is feasible but slightly less effective than the femoral approach. In this setting, an antecubital dosage of 170 μg kg−1 min−1 is comparable to the standard dosage of 140 μg kg−1 min−1 in the femoral vein. In some patients, this regimen might prevent an underestimation of lesion severity.